Findings

What do systematic reviews say?

12 questions · 12 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 8.3%GRADE not reported 0 · 0%Very low 5 · 41.7%Low 6 · 50%Moderate 0 · 0%High 0 · 0%

Terlipressin vs placebo or no intervention

All‐cause mortality · people with hepatorenal syndrome

Terlipressin may leads to lower mortality compared with placebo or no intervention (low certainty).

1 finding from 1 review

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 0.85 [0.73, 0.98]
9 studies · 534 participants
Low

Terlipressin vs placebo or no intervention

Hepatorenal syndrome · people with hepatorenal syndrome

Terlipressin may leads to lower hepatorenal syndrome compared with placebo or no intervention (low certainty).

1 finding from 1 review

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 0.63 [0.48, 0.82]
7 studies · 510 participants
Low

Terlipressin vs placebo or no intervention

Serious adverse events · people with hepatorenal syndrome

Terlipressin showed no clear difference in serious adverse events compared with placebo or no intervention (low certainty).

1 finding from 1 review

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 0.91 [0.68, 1.21]
9 studies · 534 participants
Low

Terlipressin vs placebo or no intervention

Serious adverse events: cardiovascular events · people with hepatorenal syndrome

Terlipressin may leads to higher serious cardiovascular adverse events compared with placebo or no intervention (low certainty).

1 finding from 1 review

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 7.26 [1.7, 31.05]
4 studies · 234 participants
Low

Terlipressin vs placebo or no intervention

Abdominal pain · people with hepatorenal syndrome

Terlipressin showed no clear difference in abdominal pain compared with placebo or no intervention (low certainty).

1 finding from 1 review

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 1.54 [0.97, 2.43]
4 studies · 294 participants
Low

Terlipressin vs placebo or no intervention

Diarrhoea · people with hepatorenal syndrome

Terlipressin may leads to higher diarrhoea compared with placebo or no intervention (low certainty).

1 finding from 1 review

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 5.76 [2.19, 15.15]
2 studies · 240 participants
Low

Terlipressin vs other vasoactive drugs

Mortality (all‐cause) · people with cirrhosis and hepatorenal syndrome

It is very uncertain whether terlipressin changes mortality (All‐cause) compared with other vasoactive drugs (very low certainty).

1 finding from 1 review

Terlipressin versus other vasoactive drugs for hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 0.96 [0.88, 1.06]
474 participants
Very low

Terlipressin vs other vasoactive drugs

Hepatorenal syndrome (Number of participants who did not achieve reversal of hepatorenal syndrome) · people with cirrhosis and hepatorenal syndrome

It is very uncertain whether terlipressin changes hepatorenal syndrome (Number of participants who did not achieve… compared with other vasoactive drugs (very low certainty).

1 finding from 1 review

Terlipressin versus other vasoactive drugs for hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 0.79 [0.63, 0.99]
394 participants
Very low

Terlipressin vs other vasoactive drugs

Serious adverse events · people with cirrhosis and hepatorenal syndrome

It is very uncertain whether terlipressin changes serious adverse events compared with other vasoactive drugs (very low certainty).

1 finding from 1 review

Terlipressin versus other vasoactive drugs for hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 0.96 [0.88, 1.06]
474 participants
Very low

Terlipressin vs other vasoactive drugs

Non‐serious adverse events: diarrhoea or abdominal pain, or both · people with cirrhosis and hepatorenal syndrome

It is very uncertain whether terlipressin changes non‐serious adverse events: diarrhoea or abdominal pain, or both compared with other vasoactive drugs (very low certainty).

1 finding from 1 review

Terlipressin versus other vasoactive drugs for hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 3.5 [1.19, 10.27]
221 participants
Very low

Terlipressin vs norepinephrine

Total mortalitya · hypotensive shock

It is very uncertain whether terlipressin changes total mortalitya compared with norepinephrine (very low certainty).

1 finding from 1 review

Vasopressors for hypotensive shock 2016 · Cochrane Headline outcomes only
RR 0.93 [0.69, 1.26]
7 studies · 231 participants
Very low

Intervention not reported

Albumin plus terlipressin · people with hepatorenal syndrome with decompensated liver cirrhosis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found